Drug intelligence / Profile preview

68Ga-NOTA-AE105

Development stage: Phase 2
Lead developer: Curasight
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-NOTA-AE105 is a radiopharmaceutical used for positron emission tomography (PET) imaging. It targets the urokinase plasminogen activator receptor (uPAR), which is associated with cancer aggressiveness and metastasis. The drug is composed of the peptide AE105 conjugated with the chelating agent NOTA and labeled with gallium-68. It is developed by Curasight and is being investigated for various cancers, including glioblastoma, breast cancer, and prostate cancer.

Brand names: uTRACEuTREAT
Other names: CS 001CS001CS-001

Targets

PLAUR (Urokinase plasminogen activator receptor)

Beyond the preview

Go deeper on 68Ga-NOTA-AE105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-NOTA-AE105.

Explore the full profile